Search research articles
Contact Us
Filters
Showing results (41-50 of 64) with videos related to
Page
of 7
Sort By:
The Oncologist
|
April 22, 2026
Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC
Stanislav Rosnev, Katharina Klein, Lukas Heukamp, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
June 27, 2023
Do skip-N2 metastases significantly impact overall survival and disease-free interval in N2 non-small-cell lung cancer patients? A multicentre analysis
Georg Schlachtenberger, Simon Schallenberg, Fabian Doerr, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 16, 2018
Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients
Nikolaj Frost, Antje Tessmer, Alexander Schmittel, et al.
Clinical Lung Cancer
|
April 29, 2026
A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR Mutations
Cornelia Kropf-Sanchen, Nikolaj Frost, Jonas Kuon, et al.
Neuro-Oncology
|
October 12, 2023
Immune signatures of checkpoint inhibitor-induced autoimmunity-A focus on neurotoxicity
Leonie Müller-Jensen, Axel R Schulz, Henrik E Mei, et al.
Frontiers in Oncology
|
October 9, 2023
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer
Friederike C Althoff, Lisa V Schäfer, Fabian Acker, et al.
Nature Cancer
|
January 8, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis
Mariano Provencio, Mark M Awad, Jonathan D Spicer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 15, 2023
TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading
Simon Schallenberg, Gabriel Dernbach, Mihnea P Dragomir, et al.
JAMA Oncology
|
June 4, 2021
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial
Salma K Jabbour, Ki Hyeong Lee, Nikolaj Frost, et al.
Clinical Lung Cancer
|
June 29, 2026
Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study
Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 64) with videos related to
Sort By:
Page
of 7
The Oncologist
|
April 22, 2026
Liquid biopsy-based detection of acquired MET resistance enables sequential targeted therapy in MET fusion-positive NSCLC
Stanislav Rosnev, Katharina Klein, Lukas Heukamp, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery
|
June 27, 2023
Do skip-N2 metastases significantly impact overall survival and disease-free interval in N2 non-small-cell lung cancer patients? A multicentre analysis
Georg Schlachtenberger, Simon Schallenberg, Fabian Doerr, et al.
Lung Cancer (Amsterdam, Netherlands)
|
November 16, 2018
Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients
Nikolaj Frost, Antje Tessmer, Alexander Schmittel, et al.
Clinical Lung Cancer
|
April 29, 2026
A Retrospective, Multicenter Analysis Within the National Network Genomic Medicine Lung Cancer in Germany to Detect RET Fusions as a Possible Mechanism of Resistance in Patients With EGFR Mutations
Cornelia Kropf-Sanchen, Nikolaj Frost, Jonas Kuon, et al.
Neuro-Oncology
|
October 12, 2023
Immune signatures of checkpoint inhibitor-induced autoimmunity-A focus on neurotoxicity
Leonie Müller-Jensen, Axel R Schulz, Henrik E Mei, et al.
Frontiers in Oncology
|
October 9, 2023
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancer
Friederike C Althoff, Lisa V Schäfer, Fabian Acker, et al.
Nature Cancer
|
January 8, 2026
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis
Mariano Provencio, Mark M Awad, Jonathan D Spicer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 15, 2023
TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading
Simon Schallenberg, Gabriel Dernbach, Mihnea P Dragomir, et al.
JAMA Oncology
|
June 4, 2021
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial
Salma K Jabbour, Ki Hyeong Lee, Nikolaj Frost, et al.
Clinical Lung Cancer
|
June 29, 2026
Outcomes of Platinum Plus Pemetrexed and Treatment Patterns Following First-Line Nivolumab and Ipilimumab in Pleural Mesothelioma: Real-World Results From the German MesoNet Study
Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, et al.
Page
of 7